Fife, Daniel
Waller, John
Kaplan, Sigal
Hu, Peter
Phillips, Syd
Oliveria, Susan A.
Richarz, Ute
Funding for this research was provided by:
Janssen Research and Development (US) and MAHs involved in the consortium of companies that market domperidone in Europe
Article History
First Online: 19 July 2019
Compliance with Ethical Standards
:
: Ethics committee approval for conducting the physician survey was obtained in each country, wherever applicable, as per the local requirements. For the DUS, ethics committee approval was required and obtained in the UK and Spain and was not required or obtained in the other countries because it was a retrospective database study from anonymized data. The physician survey and the DUS were conducted in accordance with all applicable regulatory requirements.
: The physician survey (ENCePP registration number: EUPAS16095) and drug utilization study (ENCePP registration number: EUPAS16062) were funded by Janssen Research and Development, LLC and MAHs involved in the consortium of companies that market domperidone in Europe.
: Daniel Fife, Peter Hu, and Ute Richarz are full time employees of Janssen Pharmaceutical Research, which markets domperidone. As full-time employees they hold stock, stock options, and pension rights from the company. Sigal Kaplan is an employee of Teva Pharmaceutical Industries Ltd. John Waller is a full-time employee of Adelphi Real World, who were commissioned to conduct the physician survey on behalf of Janssen Pharmaceutical Research. Susan A. Oliveria and Syd Phillips are full-time employees of IQVIA, who were commissioned to conduct the DUS on behalf of Janssen Pharmaceutical.